Rapid ID+AST pilot study highlighted at ECCMID 2020

Report this content

The pilot study, led by Gradientech, combined rapid ID+AST technologies – T2Bacteria (ID) and QuickMIC (AST) and compared the time-to-result to a workflow using standard laboratory methods.

The rapid diagnostic workflow provided same-shift results (9.5h) that were significantly faster than the standard workflow (53h). Interestingly, in 68% of the cases, rapid ID+AST results were available before blood cultures had turned positive.

This study highlights the potential of combining rapid ID+AST diagnostic technologies for reducing the time to targeted treatment initiation for sepsis patients.

Link to ECCMID 2020 abstract

For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80

About Gradientech
Gradientech is a diagnostics company developing the in vitro diagnostic QuickMIC® system, a new platform for antibiotic susceptibility testing based on phenotypic bacterial growth analysis. The system is expected to become the most rapid solution for determining appropriate antibiotic treatment of sepsis patients. Rapid antibiotic susceptibility testing is vital for increasing sepsis patient survival, reducing healthcare costs and lowering the spread of antibiotic resistance. www.gradientech.se